Patents by Inventor Philipp Lustenberger

Philipp Lustenberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240391938
    Abstract: This application relates to various crystalline forms of (S)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide in its free form, as well as compositions, method of making and methods of using the same. In some embodiments the crystalline forms also contain water (“hydrates”). These materials are useful in the treatment of various autoimmune diseases, including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis and psoriasis.
    Type: Application
    Filed: August 6, 2024
    Publication date: November 28, 2024
    Inventors: Nicole BIERI, Andreas KORDIKOWSKI, Bin LI, Philipp LUSTENBERGER, Rita RAMOS, Vijay SETHURAMAN, Sisi ZHANG
  • Patent number: 12084460
    Abstract: This application relates to various crystalline forms of (S)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide in its free form, as well as compositions, method of making and methods of using the same. In some embodiments the crystalline forms also contain water (“hydrates”). These materials are useful in the treatment of various autoimmune diseases, including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis and psoriasis.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: September 10, 2024
    Assignee: Novartis AG
    Inventors: Nicole Bieri, Andreas Kordikowski, Bin Li, Philipp Lustenberger, Rita Ramos, Vijay Sethuraman, Sisi Zhang
  • Publication number: 20230265067
    Abstract: Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.
    Type: Application
    Filed: February 14, 2023
    Publication date: August 24, 2023
    Inventors: Zichen JIA, Philipp LUSTENBERGER, Marie MEYER, Massimo MORATTO
  • Patent number: 11603363
    Abstract: Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: March 14, 2023
    Assignee: Novartis AG
    Inventors: Zichen Jia, Philipp Lustenberger, Marie Meyer, Massimo Moratto
  • Publication number: 20210371394
    Abstract: Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.
    Type: Application
    Filed: May 17, 2021
    Publication date: December 2, 2021
    Inventors: Zichen JIA, Philipp LUSTENBERGER, Marie MEYER, Massimo MORATTO
  • Patent number: 10723735
    Abstract: This invention relates to novel processes for synthesizing [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid and to intermediates that are used in such processes.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: July 28, 2020
    Inventors: Fabrice Gallou, Philipp Lustenberger, Christian Mathes, Qiangbiao Pan, Benli Zou
  • Publication number: 20200031824
    Abstract: This invention relates to novel processes for synthesizing [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid and to intermediates that are used in such processes.
    Type: Application
    Filed: March 29, 2018
    Publication date: January 30, 2020
    Inventors: Fabrice Gallou, Philipp Lustenberger, Christian Mathes, Qiangbiao Pan, Benli Zou
  • Patent number: 10508110
    Abstract: This invention relates to novel processes for synthesizing [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid and to intermediates that are used in such processes.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: December 17, 2019
    Assignee: NOVARTIS AG
    Inventors: Philipp Lustenberger, Christian Mathes, Zhongbo Fei, Bernard Riss, Thierry Schlama
  • Patent number: 10251868
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: April 9, 2019
    Assignee: NOVARTIS AG
    Inventors: Jun Cao, Bernhard Erb, Robin Alec Fairhurst, Arnaud Grandeury, Shinji Hatakeyama, Magdalena Koziczak-Holbro, Xinzhong Lai, Philipp Lustenberger, Bernd Ulrich Riebesehl, Nicola Tufilli, Thomas Ullrich, Xiang Wu, Jianguang Zhou
  • Publication number: 20180273530
    Abstract: This invention relates to novel processes for synthesizing [1-(4-Methanesulfonyl-2-trifluoromethyl-benzyl)-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl]-acetic acid and to intermediates that are used in such processes.
    Type: Application
    Filed: September 27, 2016
    Publication date: September 27, 2018
    Inventors: Philipp Lustenberger, Christian Mathes, Zhongbo Fei, Bernard Riss, Thierry Schlama
  • Publication number: 20180140582
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Application
    Filed: January 22, 2018
    Publication date: May 24, 2018
    Applicant: NOVARTIS AG
    Inventors: Jun CAO, Bernhard ERB, Robin Alec FAIRHURST, Arnaud GRANDEURY, Shinji HATAKEYAMA, Magdalena KOZICZAK-HOLBRO, Xinzhong LAI, Philipp LUSTENBERGER, Bernd Ulrich RIEBESEHL, Nicola TUFILLI, Thomas ULLRICH, Xiang WU, Jianguang ZHOU
  • Patent number: 9913828
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: March 13, 2018
    Assignee: NOVARTIS AG
    Inventors: Jun Cao, Bernhard Erb, Robin Alec Fairhurst, Arnaud Grandeury, Shinji Hatakeyama, Magdalena Koziczak-Holbro, Xinzhong Lai, Philipp Lustenberger, Bernd Ulrich Riebesehl, Nicola Tufilli, Thomas Ullrich, Xiang Wu, Jianguang Zhou
  • Publication number: 20160279107
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Application
    Filed: June 10, 2016
    Publication date: September 29, 2016
    Applicant: NOVARTIS AG
    Inventors: Jun CAO, Bernhard ERB, Robin Alec FAIRHURST, Arnaud GRANDEURY, Shinji HATAKEYAMA, Magdalena KOZICZAK-HOLBRO, Xinzhong LAI, Philipp LUSTENBERGER, Bernd Ulrich RIEBESEHL, Nicola TUFILLI, Thomas ULLRICH, Xiang Wu, Jianguang ZHOU
  • Publication number: 20160075670
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Application
    Filed: November 20, 2015
    Publication date: March 17, 2016
    Applicant: NOVARTIS AG
    Inventors: Jun CAO, Bernhard ERB, Robin Alec FAIRHURST, Arnaud GRANDEURY, Shinji HATAKEYAMA, Magdalena KOZICZAK-HOLBRO, Philipp LUSTENBERGER, Bernd RIEBESEHL, Nicola TUFILLI, Thomas ULLRICH, Xiang WU, Jianguang ZHOU
  • Publication number: 20150336914
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Application
    Filed: August 3, 2015
    Publication date: November 26, 2015
    Applicant: NOVARTIS AG
    Inventors: Jun CAO, Bernhard ERB, Robin Alec FAIRHURST, Arnaud GRANDEURY, Shinji HATAKEYAMA, Magdalena KOZICZAK-HOLBRO, Philipp LUSTENBERGER, Bernd RIEBESEHL, Nicola TUFILLI, Thomas ULLRICH, Xiang WU, Jianguang ZHOU
  • Publication number: 20150094346
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Application
    Filed: December 10, 2014
    Publication date: April 2, 2015
    Applicant: NOVARTIS AG
    Inventors: Jun CAO, Bernhard ERB, Robin Alec FAIRHURST, Arnaud GRANDEURY, Shinji HATAKEYAMA, Magdalena KOZICZAK-HOLBRO, Philipp LUSTENBERGER, Bernd RIEBESEHL, Nicola TUFILLI, Thomas ULLRICH, Xiang WU, Jianguang ZHOU
  • Patent number: 8933108
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: January 13, 2015
    Assignee: Novartis AG
    Inventors: Jun Cao, Bernhard Erb, Robin Alec Fairhurst, Arnaud Grandeury, Shinji Hatakeyama, Magdalena Koziczak-Holbro, Xinzhong Lai, Philipp Lustenberger, Bernd Riebesehl, Nicola Tufilli, Thomas Ullrich, Xiang Wu, Jianguang Zhou
  • Patent number: 8618132
    Abstract: The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: December 31, 2013
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Dirk Stenkamp, Stephan Georg Mueller, Gerald Juergen Roth, Thorsten Lehmann-Lintz, Klaus Rudolf, Philipp Lustenberger, Kristen Arndt, Ralf R. H. Lotz, Martin Lenter
  • Publication number: 20130245080
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compound of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and pharmaceutical compositions.
    Type: Application
    Filed: September 5, 2012
    Publication date: September 19, 2013
    Applicant: NOVARTIS AG
    Inventors: Jun CAO, Bernhard ERB, Robin Alec FAIRHURST, Arnaud GRANDEURY, Shinji HATAKEYAMA, Magdalena KOZICZAK-HOLBRO, Xinzhong LAI, Philipp LUSTENBERGER, Bernd RIEBESEHL, Nicola TUFILLI, Thomas ULLRICH, Xiang WU, Jianguang ZHOU
  • Patent number: 8084487
    Abstract: The present invention relates to a process for the production of carbamic acid (2-chloroethyl)(3-oxocyclohexyl)-alkyl ester enantiomers and of 1-carbalkoxy-4-ketoperhydroindole enantiomers.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: December 27, 2011
    Assignee: Novartis AG
    Inventors: Ernst Kuesters, Murat Acemoglu, Philipp Lustenberger, Gottfried Sedelmeier, Beat Schmitz, Gerhard Penn